Compare GSK plc (GSK) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? GSK plc trades at $46.54 (market cap $91.88B), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.22 (market cap $4.35B). The key difference: GSK plc is far larger — about 21.1× State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF's market cap, and GSK plc pays a 3.9% dividend while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF for 41 Days on average.
| GSK | SJNK | |
|---|---|---|
Market Cap | $91.88B | $4.35B |
Volume | 7,730,529 | 3,211,044 |
Sector | Health | Fixed Income |
52-Week High | $61.18 | $25.57 |
52-Week Low | $43.24 | $24.13 |
Typical Hold Time | 93 Days | 41 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
SJNK (SPDR Bloomberg Short Term High Yield Bond ETF) trades at $24.21, showing minimal daily movement with a 0.04% gain. Technical indicators signal bearish momentum with moving averages heavily favoring selling pressure, though oscillators remain neutral. The ETF continues its dividend distribution pattern with recent payments of $0.14-$0.15 per share. Institutional activity shows mixed sentiment with Cetera Investment Advisers maintaining a $17.83 million position while Balefire LLC significantly reduced its holdings by 74.7% in recent quarters.
The ETF faces headwinds from bearish technical signals despite attractive yield comparisons to Treasury bonds. Current price consolidation near $24 support levels suggests cautious investor sentiment. Dividend consistency provides income appeal, but institutional selling pressure and technical weakness indicate near-term challenges for price appreciation amid competitive fixed-income alternatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
